Adaptimmune Historical Balance Sheet

ADAP Stock

USD 0.21 0.01 4.55%

Trend analysis of Adaptimmune Therapeutics Plc balance sheet accounts such as Other Current Liab of 22.5 M, Total Current Liabilities of 46.5 M or Total Stockholder Equity of 11.3 M provides information on Adaptimmune Therapeutics' total assets, liabilities, and equity, which is the actual value of Adaptimmune Therapeutics to its prevalent stockholders. By breaking down trends over time using Adaptimmune Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Adaptimmune Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptimmune Therapeutics is a good buy for the upcoming year.

Adaptimmune Therapeutics Inventory

7.69 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Adaptimmune Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Adaptimmune Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Adaptimmune Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Adaptimmune Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Adaptimmune currently owns. An asset can also be divided into two categories, current and non-current.

Adaptimmune Therapeutics Balance Sheet Chart

At this time, Adaptimmune Therapeutics' Property Plant And Equipment Gross is relatively stable compared to the past year. As of 03/30/2025, Total Current Assets is likely to grow to about 227.5 M, while Total Stockholder Equity is likely to drop slightly above 11.3 M.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Adaptimmune Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Adaptimmune Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Adaptimmune Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Adaptimmune Therapeutics Plc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Adaptimmune Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	30.8M	28.9M	38.8M	22.5M
Total Assets	328.9M	282.6M	246.0M	268.3M

Other Current Liab Total Assets

Adaptimmune Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Short Term Debt	Property Plant Equipment	Net Tangible Assets
Total Assets		0.26	0.6	0.72	0.66	-0.38	-0.55	0.58	0.63	0.65	0.38	0.96	0.14	0.81	0.56	0.7	0.74	0.6	0.45	0.99	0.68	0.19	0.25	0.15	0.48	0.81
Other Current Liab	0.26		0.75	-0.15	0.52	0.2	-0.55	0.27	-0.09	0.51	-0.07	0.12	0.14	0.44	0.46	0.47	0.55	0.55	0.49	0.18	0.45	0.03	0.48	-0.04	0.49	-0.06
Total Current Liabilities	0.6	0.75		0.08	0.76	-0.15	-0.68	0.69	0.36	0.75	0.15	0.44	0.38	0.7	0.65	0.59	0.73	0.77	0.67	0.51	0.68	0.14	0.46	0.09	0.7	0.19
Total Stockholder Equity	0.72	-0.15	0.08		0.14	-0.27	0.13	0.23	0.51	0.18	0.63	0.82	-0.16	0.27	-0.15	0.28	0.19	-0.11	-0.18	0.78	0.1	0.51	-0.41	0.3	-0.14	0.97
Property Plant And Equipment Net	0.66	0.52	0.76	0.14		0.03	-0.85	0.73	0.17	0.99	0.21	0.42	0.41	0.86	0.74	0.83	0.94	0.79	0.79	0.53	0.81	-0.22	0.52	-0.31	0.81	0.26
Net Debt	-0.38	0.2	-0.15	-0.27	0.03		0.05	-0.1	-0.87	0.08	0.05	-0.46	-0.28	-0.16	-0.24	0.1	-0.05	-0.23	-0.05	-0.44	-0.18	-0.25	0.0	-0.77	-0.01	-0.28
Retained Earnings	-0.55	-0.55	-0.68	0.13	-0.85	0.05		-0.59	-0.16	-0.82	0.1	-0.34	-0.39	-0.91	-0.93	-0.69	-0.91	-0.94	-0.95	-0.44	-0.94	0.39	-0.87	0.3	-0.93	-0.06
Accounts Payable	0.58	0.27	0.69	0.23	0.73	-0.1	-0.59		0.29	0.77	0.39	0.43	0.19	0.7	0.5	0.59	0.7	0.58	0.62	0.49	0.66	0.06	0.3	-0.04	0.63	0.35
Cash	0.63	-0.09	0.36	0.51	0.17	-0.87	-0.16	0.29		0.15	0.27	0.68	0.3	0.39	0.27	0.08	0.22	0.31	0.19	0.68	0.37	0.52	-0.05	0.69	0.21	0.55
Non Current Assets Total	0.65	0.51	0.75	0.18	0.99	0.08	-0.82	0.77	0.15		0.29	0.42	0.35	0.86	0.69	0.82	0.93	0.74	0.78	0.52	0.8	-0.17	0.47	-0.32	0.81	0.3
Other Assets	0.38	-0.07	0.15	0.63	0.21	0.05	0.1	0.39	0.27	0.29		0.38	-0.16	0.24	-0.26	0.18	0.11	-0.18	-0.01	0.36	0.11	0.55	-0.46	0.1	0.09	0.6
Cash And Short Term Investments	0.96	0.12	0.44	0.82	0.42	-0.46	-0.34	0.43	0.68	0.42	0.38		0.0	0.65	0.4	0.54	0.53	0.43	0.24	0.99	0.52	0.31	0.11	0.29	0.27	0.88
Net Receivables	0.14	0.14	0.38	-0.16	0.41	-0.28	-0.39	0.19	0.3	0.35	-0.16	0.0		0.25	0.38	-0.08	0.36	0.39	0.48	0.08	0.35	-0.12	0.31	0.05	0.35	-0.11
Common Stock Total Equity	0.81	0.44	0.7	0.27	0.86	-0.16	-0.91	0.7	0.39	0.86	0.24	0.65	0.25		0.81	0.76	0.92	0.85	0.87	0.72	0.97	-0.12	0.64	-0.15	0.88	0.45
Non Current Liabilities Total	0.56	0.46	0.65	-0.15	0.74	-0.24	-0.93	0.5	0.27	0.69	-0.26	0.4	0.38	0.81		0.68	0.82	0.98	0.83	0.48	0.84	-0.42	0.87	-0.18	0.81	0.0
Other Current Assets	0.7	0.47	0.59	0.28	0.83	0.1	-0.69	0.59	0.08	0.82	0.18	0.54	-0.08	0.76	0.68		0.82	0.7	0.5	0.61	0.62	-0.23	0.42	-0.32	0.58	0.34
Other Stockholder Equity	0.74	0.55	0.73	0.19	0.94	-0.05	-0.91	0.7	0.22	0.93	0.11	0.53	0.36	0.92	0.82	0.82		0.85	0.82	0.63	0.88	-0.26	0.66	-0.26	0.81	0.34
Total Liab	0.6	0.55	0.77	-0.11	0.79	-0.23	-0.94	0.58	0.31	0.74	-0.18	0.43	0.39	0.85	0.98	0.7	0.85		0.86	0.52	0.87	-0.31	0.84	-0.13	0.85	0.05
Property Plant And Equipment Gross	0.45	0.49	0.67	-0.18	0.79	-0.05	-0.95	0.62	0.19	0.78	-0.01	0.24	0.48	0.87	0.83	0.5	0.82	0.86		0.34	0.95	-0.28	0.81	-0.26	0.96	0.02
Total Current Assets	0.99	0.18	0.51	0.78	0.53	-0.44	-0.44	0.49	0.68	0.52	0.36	0.99	0.08	0.72	0.48	0.61	0.63	0.52	0.34		0.6	0.25	0.19	0.24	0.37	0.85
Common Stock	0.68	0.45	0.68	0.1	0.81	-0.18	-0.94	0.66	0.37	0.8	0.11	0.52	0.35	0.97	0.84	0.62	0.88	0.87	0.95	0.6		-0.17	0.75	-0.15	0.93	0.3
Short Long Term Debt Total	0.19	0.03	0.14	0.51	-0.22	-0.25	0.39	0.06	0.52	-0.17	0.55	0.31	-0.12	-0.12	-0.42	-0.23	-0.26	-0.31	-0.28	0.25	-0.17		-0.58	0.67	-0.18	0.47
Common Stock Shares Outstanding	0.25	0.48	0.46	-0.41	0.52	0.0	-0.87	0.3	-0.05	0.47	-0.46	0.11	0.31	0.64	0.87	0.42	0.66	0.84	0.81	0.19	0.75	-0.58		-0.31	0.74	-0.23
Short Term Debt	0.15	-0.04	0.09	0.3	-0.31	-0.77	0.3	-0.04	0.69	-0.32	0.1	0.29	0.05	-0.15	-0.18	-0.32	-0.26	-0.13	-0.26	0.24	-0.15	0.67	-0.31		-0.24	0.26
Property Plant Equipment	0.48	0.49	0.7	-0.14	0.81	-0.01	-0.93	0.63	0.21	0.81	0.09	0.27	0.35	0.88	0.81	0.58	0.81	0.85	0.96	0.37	0.93	-0.18	0.74	-0.24		0.06
Net Tangible Assets	0.81	-0.06	0.19	0.97	0.26	-0.28	-0.06	0.35	0.55	0.3	0.6	0.88	-0.11	0.45	0.0	0.34	0.34	0.05	0.02	0.85	0.3	0.47	-0.23	0.26	0.06

Click cells to compare fundamentals

Adaptimmune Therapeutics Account Relationship Matchups

Adaptimmune Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	451.1M	469.5M	328.9M	282.6M	246.0M	268.3M
Other Current Liab	24.3M	27.6M	30.8M	28.9M	38.8M	22.5M
Total Current Liabilities	39.1M	62.5M	64.5M	72.8M	64.5M	46.5M
Total Stockholder Equity	341.2M	206.0M	81.9M	39.5M	11.8M	11.3M
Property Plant And Equipment Net	46.7M	51.4M	71.5M	71.7M	51.2M	36.3M
Net Debt	(33.2M)	(124.5M)	(85.0M)	(118.8M)	(67.2M)	(70.5M)
Retained Earnings	(585.8M)	(743.8M)	(909.3M)	(1.0B)	(1.1B)	(1.0B)
Accounts Payable	6.4M	8.1M	4.8M	8.1M	8.7M	5.8M
Cash	56.9M	149.9M	108.0M	144.0M	91.1M	111.9M
Non Current Assets Total	53.0M	54.1M	73.5M	75.1M	57.8M	40.8M
Other Assets	7.0M	4.6M	1.7M	1.6M	1.8M	1.7M
Cash And Short Term Investments	368.2M	369.6M	204.6M	146.9M	151.6M	200.2M
Net Receivables	139K	752K	7.4M	46.9M	1.5M	1.4M
Common Stock Total Equity	939K	943K	1.3M	1.3M	1.5M	1.6M
Liabilities And Stockholders Equity	451.1M	469.5M	328.9M	282.6M	246.0M	268.3M
Non Current Liabilities Total	70.8M	201.0M	182.5M	170.3M	169.6M	178.1M
Other Current Assets	34.0M	54.2M	51.5M	13.7M	27.8M	21.8M
Other Stockholder Equity	935.7M	959.6M	990.7M	1.1B	1.1B	583.9M
Total Liab	109.9M	263.6M	247.0M	243.1M	234.1M	245.8M
Property Plant And Equipment Gross	46.7M	51.4M	71.5M	130.9M	120.9M	126.9M
Total Current Assets	398.2M	415.5M	255.4M	207.6M	188.2M	227.5M
Accumulated Other Comprehensive Income	(10.0M)	(11.1M)	(875K)	(3.7M)	(1.9M)	(1.8M)
Common Stock	1.3M	1.3M	1.4M	1.9M	2.1M	2.2M
Short Long Term Debt Total	23.7M	25.5M	23.1M	25.2M	24.0M	36.4M
Common Stock Shares Outstanding	854.8M	934.8M	967.2M	1.2B	1.5B	1.6B
Short Term Debt	5.5M	4.6M	5.5M	5.4M	4.7M	4.6M
Property Plant Equipment	31.1M	27.8M	30.5M	71.5M	82.3M	86.4M
Net Tangible Assets	121.4M	339.5M	205.0M	81.4M	93.7M	89.0M
Non Currrent Assets Other	4.6M	1.7M	1.6M	3.0M	2.7M	3.5M
Short Term Investments	311.3M	219.6M	96.6M	2.9M	60.5M	108.1M
Other Liab	598K	49.9M	177.9M	162.2M	186.5M	195.8M
Current Deferred Revenue	2.8M	22.2M	23.5M	29.0M	12.3M	14.7M
Inventory	2.1M	746K	1.3M	1.3M	7.3M	7.7M
Intangible Assets	1.7M	1M	442K	330K	3.9M	4.1M
Capital Surpluse	574.2M	585.6M	935.7M	959.6M	1.1B	657.5M
Retained Earnings Total Equity	(318.5M)	(455.7M)	(585.8M)	(743.8M)	(669.5M)	(636.0M)
Non Current Liabilities Other	70.8M	201.0M	1.3M	1.4M	4.3M	4.1M
Net Invested Capital	341.2M	206.0M	81.9M	39.5M	62.1M	59.0M
Net Working Capital	359.1M	352.9M	190.9M	134.8M	123.6M	161.0M

Pair Trading with Adaptimmune Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptimmune Stock

0.76

CDIOW

Cardio Diagnostics

Pair Corr

Moving against Adaptimmune Stock

0.64	LUCD	Lucid Diagnostics	Pair Corr
0.49	WM	Waste Management	Pair Corr
0.4	GE	GE Aerospace	Pair Corr

The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.

The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptimmune Historical Balance Sheet

Adaptimmune Therapeutics Inventory

7.69 Million

About Adaptimmune Balance Sheet Analysis

Adaptimmune Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Adaptimmune Therapeutics balance sheet Correlations

Adaptimmune Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptimmune Therapeutics balance sheet Accounts

Pair Trading with Adaptimmune Therapeutics

Moving together with Adaptimmune Stock

Moving against Adaptimmune Stock

Additional Tools for Adaptimmune Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.98	Non Current Liabilities Total
Net Tangible Assets	+ 0.97	Total Stockholder Equity
Common Stock	+ 0.97	Common Stock Total Equity

Property Plant And Equipment Gross	- 0.95	Retained Earnings
Common Stock	- 0.94	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Property Plant Equipment	- 0.93	Retained Earnings
Non Current Liabilities Total	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.91	Retained Earnings